162 F. Supp. 3d 704
N.D. Ill.2016Background
- Endo (branded) owned Penwest patents covering formulations of Opana ER; Impax (first-filer) submitted a Paragraph IV ANDA challenging those patents and triggered Hatch‑Waxman litigation and a 30‑month stay.
- On June 8, 2010 Endo and Impax settled via two simultaneous agreements: a Settlement & License Agreement (SLA) and a Development & Co‑Promotion Agreement (DCA). Impax agreed to delay generic entry until Jan 1, 2013 (or other contingent events).
- The SLA contained an "Endo Credit" contingent payment to Impax (higher payment if branded sales fell), a royalties provision that could require Impax to pay Endo if branded sales were high, and a No‑AG provision preventing Endo from launching an authorized generic during Impax’s 180‑day exclusivity period.
- The DCA provided a $10 million upfront payment from Endo to Impax for collaboration on a Parkinson’s drug, paid regardless of whether Impax entered the market.
- Endo switched to a crush‑resistant Opana ER CRF, which was not AB‑rated with the original Opana ER; branded sales shifted to CRF and Impax ultimately received over $102 million under the Endo Credit when it entered in Jan 2013.
- DPPs sued under the Sherman Act; EPPs sued under multiple state antitrust, consumer protection, and unjust enrichment laws. Defendants moved to dismiss both amended complaints under Rule 12(b)(6).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the settlement contained a reverse payment under Actavis | The Endo Credit, No‑AG Agreement, and $10M DCA together are a reverse payment for delaying generic entry | The provisions are not payments: no immediate cash, contingent terms, possible reverse royalty, and No‑AG has no independent value to Impax | Court: Plausibly a reverse payment when agreements are read together; denial of dismissal on this ground |
| Whether the payment was "large" and "unjustified" under Actavis | The combined value (estimated $43–$59M; minimum ~$33M) far exceeds litigation cost savings and DCA $10M was not tied to services | Defendants: each component is small or justified as normal settlement (litigation avoidance, legitimate services) | Court: Plaintiffs plausibly pleaded a large, unjustified reverse payment; dismissal denied |
| Whether Plaintiffs pleaded antitrust injury (causal delay and overcharge) | Reverse payment was intended to and did delay competition, enabling Endo’s CRF switch and supra‑competitive prices causing injury to purchasers | Defendants: Plaintiffs must allege that Impax would have lawfully launched earlier (i.e., patents were weak) | Court: Under Actavis plaintiffs need not prove patent invalidity at pleading stage; allegations suffice to infer anticompetitive harm; dismissal denied for antitrust claims |
| Whether EPPs’ state‑law claims survive procedural and substantive challenges | EPPs assert state antitrust, consumer protection, and unjust enrichment claims across many jurisdictions | Defendants raise Article III standing, Illinois Brick, state‑specific limitations, procedural restrictions, and failure to plead elements | Court: Article III standing adequate; but indirect‑purchaser claims dismissed with prejudice for Illinois, Puerto Rico, Rhode Island (prospective repealer), Kansas, Mississippi; Utah claim, all consumer‑protection and unjust enrichment claims dismissed with leave to replead where indicated |
Key Cases Cited
- FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013) (rule‑of‑reason scrutiny of large, unjustified reverse‑payment patent settlements)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility pleading standard)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading rule; courts need not accept legal conclusions)
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (1977) (only direct purchasers can recover under federal antitrust law)
- California v. ARC America Corp., 490 U.S. 93 (1989) (states may allow indirect‑purchaser antitrust suits despite Illinois Brick)
- Janssen Pharmaceutica, N.V. v. Apotex, Inc., 540 F.3d 1353 (Fed. Cir. 2008) (first‑filer exclusivity triggers)
- King Drug Co. of Florence v. Smithkline Beecham Corp., 791 F.3d 388 (3d Cir. 2015) (value of exclusivity/authorized generic issues in reverse‑payment context)
- Geinosky v. City of Chicago, 675 F.3d 743 (7th Cir. 2012) (documents integral to complaint may be considered on motion to dismiss)